NASDAQ:BSTG - Nasdaq -
0.23
-0.07 (-23.33%)
The current stock price of BSTG is 0.23 null. In the past month the price decreased by -25.32%. In the past year, price decreased by -75.53%.
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.
Biostage Inc.
84 October Hill Road Suite 11
Holliston MA 01746
CEO: James McGorry
Phone: 774-233-7300
The current stock price of BSTG is 0.23 null. The price decreased by -23.33% in the last trading session.
The exchange symbol of Biostage Inc. is BSTG and it is listed on the Nasdaq exchange.
BSTG stock is listed on the Nasdaq exchange.
Biostage Inc. (BSTG) has a market capitalization of 8.98M null. This makes BSTG a Nano Cap stock.
Biostage Inc. (BSTG) has a resistance level at 0.3. Check the full technical report for a detailed analysis of BSTG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BSTG does not pay a dividend.
Biostage Inc. (BSTG) will report earnings on 2022-04-11.
Biostage Inc. (BSTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
ChartMill assigns a fundamental rating of 1 / 10 to BSTG. BSTG has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months BSTG reported a non-GAAP Earnings per Share(EPS) of -0.614. The EPS increased by 7.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -25627.78% | ||
ROA | -297.23% | ||
ROE | -1081.17% | ||
Debt/Equity | 0 |